275 related articles for article (PubMed ID: 19944395)
1. Challenging the dogma of high target doses in the treatment of heart failure: is more always better?
Follath F
Arch Cardiovasc Dis; 2009 Nov; 102(11):785-9. PubMed ID: 19944395
[TBL] [Abstract][Full Text] [Related]
2. A review of heart failure management in the elderly population.
Cheng JW; Nayar M
Am J Geriatr Pharmacother; 2009 Oct; 7(5):233-49. PubMed ID: 19948300
[TBL] [Abstract][Full Text] [Related]
3. Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure.
Lenzen MJ; Boersma E; Reimer WJ; Balk AH; Komajda M; Swedberg K; Follath F; Jimenez-Navarro M; Simoons ML; Cleland JG
Eur Heart J; 2005 Dec; 26(24):2706-13. PubMed ID: 16183692
[TBL] [Abstract][Full Text] [Related]
4. Comparison of medical therapy dosing in outpatients cared for in cardiology practices with heart failure and reduced ejection fraction with and without device therapy: report from IMPROVE HF.
Heywood JT; Fonarow GC; Yancy CW; Albert NM; Curtis AB; Gheorghiade M; Inge PJ; McBride ML; Mehra MR; O'Connor CM; Reynolds D; Walsh MN
Circ Heart Fail; 2010 Sep; 3(5):596-605. PubMed ID: 20634483
[TBL] [Abstract][Full Text] [Related]
5. Awareness and perception of heart failure among European cardiologists, internists, geriatricians, and primary care physicians.
Remme WJ; McMurray JJ; Hobbs FD; Cohen-Solal A; Lopez-Sendon J; Boccanelli A; Zannad F; Rauch B; Keukelaar K; Macarie C; Ruzyllo W; Cline C;
Eur Heart J; 2008 Jul; 29(14):1739-52. PubMed ID: 18506054
[TBL] [Abstract][Full Text] [Related]
6. The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy.
Khan NA; McAlister FA; Campbell NR; Feldman RD; Rabkin S; Mahon J; Lewanczuk R; Zarnke KB; Hemmelgarn B; Lebel M; Levine M; Herbert C;
Can J Cardiol; 2004 Jan; 20(1):41-54. PubMed ID: 14968142
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
8. [Addition of beta blockers in chronic heart failure].
Missault LH; van Veldhuisen DJ
Ned Tijdschr Geneeskd; 2000 Sep; 144(40):1905-10. PubMed ID: 11045137
[TBL] [Abstract][Full Text] [Related]
9. Comparison of treatment initiation with bisoprolol vs. enalapril in chronic heart failure patients: rationale and design of CIBIS-III.
Willenheimer R; Erdmann E; Follath F; Krum H; Ponikowski P; Silke B; Van Veldhuisen DJ; Van De Ven L; Verkenne P; Lechat P;
Eur J Heart Fail; 2004 Jun; 6(4):493-500. PubMed ID: 15182776
[TBL] [Abstract][Full Text] [Related]
10. How well are chronic heart failure patients being managed?
Fonarow GC
Rev Cardiovasc Med; 2006; 7 Suppl 1():S3-11. PubMed ID: 16955055
[TBL] [Abstract][Full Text] [Related]
11. Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF study.
Krum H; Shi H; Pitt B; McMurray J; Swedberg K; van Veldhuisen DJ; Vincent J; Pocock S; Zannad F;
Circ Heart Fail; 2013 Jul; 6(4):711-8. PubMed ID: 23625945
[TBL] [Abstract][Full Text] [Related]
12. [Temporal trends in pharmacological therapy in the IN-CHF registry from 1995 to 2005].
Fabbri G; Gorini M; Maggioni AP; Di Lenarda A;
G Ital Cardiol (Rome); 2007 Feb; 8(2):102-6. PubMed ID: 17402354
[TBL] [Abstract][Full Text] [Related]
13. Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design.
Fonarow GC; Abraham WT; Albert NM; Gattis WA; Gheorghiade M; Greenberg B; O'Connor CM; Yancy CW; Young J
Am Heart J; 2004 Jul; 148(1):43-51. PubMed ID: 15215791
[TBL] [Abstract][Full Text] [Related]
14. AT1 receptor blockade for the prevention of cardiovascular events after myocardial infarction.
Azadpour M; Lamas GA
Expert Rev Cardiovasc Ther; 2004 Nov; 2(6):891-902. PubMed ID: 15500434
[TBL] [Abstract][Full Text] [Related]
15. Drug therapy of chronic heart failure in the elderly: the current state of clinical-trial evidence.
Dulin BR; Krum H
Curr Opin Cardiol; 2006 Jul; 21(4):393-9. PubMed ID: 16755210
[TBL] [Abstract][Full Text] [Related]
16. A survey of outpatient management of elderly heart failure patients in Poland-treatment patterns.
Rywik TM; Rywik SL; Korewicki J; Broda G; Sarnecka A; Drewla J
Int J Cardiol; 2004 Jun; 95(2-3):177-84. PubMed ID: 15193817
[TBL] [Abstract][Full Text] [Related]
17. [Pharmacological therapy of chronic heart failure in the elderly].
Sabbadini G; Di Lenarda A; Metra M; Nodari S; Moretti M; Brentana L; Dei Cas L; Sinagra G
Ital Heart J; 2004 Dec; 5 Suppl 10():37S-51S. PubMed ID: 15712511
[TBL] [Abstract][Full Text] [Related]
18. Improved guideline adherence to pharmacotherapy of chronic systolic heart failure in general practice--results from a cluster-randomized controlled trial of implementation of a clinical practice guideline.
Peters-Klimm F; Müller-Tasch T; Remppis A; Szecsenyi J; Schellberg D
J Eval Clin Pract; 2008 Oct; 14(5):823-9. PubMed ID: 19018915
[TBL] [Abstract][Full Text] [Related]
19. [Adaptation of guidelines for the treatment of chronic heart failure in a specialized heart failure clinic].
Pölzl G; Gouya G; Hügel H; Frick M; Ulmer H; Pachinger O
Wien Klin Wochenschr; 2002 Oct; 114(19-20):833-9. PubMed ID: 12503474
[TBL] [Abstract][Full Text] [Related]
20. What does ATLAS really tell us about "high" dose angiotensin-converting enzyme inhibition in heart failure?
Nicklas JM; Cohn JN; Pitt B
J Card Fail; 2000 Jun; 6(2):165-8. PubMed ID: 10908091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
